Potent Dimerization Inhibitors for HIV-1 Protease

Back to all technologies
Download as PDF
64554
Advances in the treatment of HIV/AIDS with HIV-1 protease inhibitors in combination with reverse transcriptase inhibitors, known as highly active antiretroviral therapy (HAART), has resulted in improved life expectancy and significantly reduced HIV/AIDS-related mortality in the developed world. Unfortunately, HAART suffers from adverse drug side effects, poor oral bioavailability, and drug interactions. Also, drug-resistant HIV-1 variants have begun to emerge. Development of antiretroviral therapy with broad-spectrum activity and minimal side effects is needed for current and future HIV/AIDS treatment.

Purdue University researchers have created Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naive and treatment-experienced adults and adolescents. It is also used in patients with drug-resistant HIV.

The researchers have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug-resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad spectrum activity against highly cross-resistant mutant.

Advantages:
-Decreased adverse side effects
-Effective against multidrug-resistant HIV-1 variants
-Improved bioavailability
-Superior pharmacokinetic properties

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Drug Development
-HIV/AIDS Treatment
Jan 12, 2010
NATL-Patent
United States
9,808,527
Nov 7, 2017

Nov 20, 2007
PCT-Patent
WO
(None)
(None)

Nov 20, 2007
NATL-Patent
European Patent
(None)
(None)

Nov 20, 2007
DIV-Patent
European Patent
(None)
(None)

Jun 22, 2007
Provisional-Patent
United States
(None)
(None)

Nov 21, 2006
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org